Basis: (FMP quote price / unrounded diluted TTM EPS) / five-year diluted EPS CAGR in percent, from annual statements through the period end shown. Source: stored company filings and market data; unavailable inputs remain N/A.
The PEG ratio is N/A as of 2026-10-06T16:57:38.314Z.
Calculation as of: 2026-10-06T16:57:38.314Z.
Quote observation: 2026-10-06T16:37:08.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 7cda135bbdc40ab96f6f5c38083b7dd78a9f140dcd8a254691991f8eaa2b9dc4
PEG RATIO
N/A
Neuphoria Therapeutics Inc.
Market Cap
$18.65M
PEG Ratio
N/A
| NAME | MARKET CAP | PEG RATIO |
|---|---|---|
| Neuphoria Therapeutics Inc. (NEUP) | $18.65M | N/A |
| NextCure, Inc. (NXTC)vs › | $18.95M | N/A |
| Estrella Immunopharma, Inc. (ESLA)vs › | $19.53M | N/A |
| Cosmos Health Inc. (COSM)vs › | $17.73M | N/A |
| P3 Health Partners Inc. (PIII)vs › | $19.67M | N/A |
| Actuate Therapeutics Inc (ACTU)vs › | $20.01M | N/A |
| Lipocine Inc. (LPCN)vs › | $17.23M | N/A |
| Marker Therapeutics, Inc. (MRKR)vs › | $17.01M | N/A |
| PAVmed Inc. (PAVM)vs › | $16.98M | N/A |
| Palatin Technologies, Inc. (PTN)vs › | $16.73M | N/A |
PEG Ratio
N/A
P/E Ratio
N/A
PEG Ratio = P/E Ratio / 5-Year Diluted EPS CAGR (%)
The PEG ratio divides the price-to-earnings ratio by the company's five-year compound annual growth rate of diluted EPS, expressed in percent. A P/E of 20 and a five-year diluted EPS CAGR of 10% give a PEG of 2.0. The growth is reported, historical earnings growth from annual statements, not an analyst forecast. A PEG near 1 is often read as fairly priced for its growth; lower can mean cheaper relative to growth. The ratio is N/A when the P/E is unavailable or not positive, or when the five-year diluted EPS CAGR is unavailable or not positive. Each day of the history uses the CAGR that was known on that day.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
